Red X iconGreen tick iconYellow tick icon

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Tel 64 3 364 0579


Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264

Hock, B. D., Goddard, L., MacPherson, S. A., Strother, M., Gibbs, D., Pearson, J. F., & McKenzie, J. L. (2023). Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab. PLoS ONE, 18(9), e0290793. doi: 10.1371/journal.pone.0290793

Sulit, A. K., Daigneault, M., Allen-Vercoe, E., Silander, O. K., Hock, B., McKenzie, J., Pearson, J., Frizelle, F. A., Schmeier, S., & Purcell, R. (2023). Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment. npj Biofilms & Microbiomes, 9, 59. doi: 10.1038/s41522-023-00429-w

Keenan, J. I., Aitchison, A., Frizelle, F. A., & Hock, B. D. (2023). Detection of chitinase 3-like 1 in symptomatic primary care patient faecal samples is not a reliable biomarker of colonic lesions. Asian Pacific Journal of Cancer Prevention, 24(7), 2289-2293. doi: 10.31557/APJCP.2023.24.7.2289

Ghodsian, N., Yeandle, A., Hock, B. D., & Gieseg, S. P. (2022). CD36 down regulation by the macrophage antioxidant 7,8-dihydroneopterin through modulation of PPAR-γ activity. Free Radical Research, 56(5-6), 366-377. doi: 10.1080/10715762.2022.2114904

Back to top